ResMed price target lowered to $225 from $254 at Baird
Baird lowered the firm’s price target on ResMed (RMD) to $225 from $254 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results and…
Fiscal Year: July - June
ResMed Inc. (RMD), listed on the NYSE, has a market capitalization of $29.56B. As of May 13, 2026, the stock is trading at $203.79 per share@else an unavailable price , offering investors a clear view of its current market value. ResMed Inc. is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 19.65, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. ResMed Inc. also offers a dividend yield of 1.21%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that ResMed Inc. (RMD) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for ResMed Inc. is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for ResMed Inc., Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for ResMed Inc. is 16.85, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, ResMed Inc. (RMD) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether ResMed Inc. (RMD) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of ResMed Inc. (RMD) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of ResMed Inc.. To access the full SS Score, consider upgrading your subscription.
ResMed Inc. is a significant player in the industry sector, with a market capitalization of $29.56B and a competitive P/E ratio of 19.65. Investors should compare these metrics with industry peers to gauge whether ResMed Inc. is outperforming or underperforming within its sector.
Baird lowered the firm’s price target on ResMed (RMD) to $225 from $254 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results and…
Stifel lowered the firm’s price target on ResMed (RMD) to $235 from $265 and keeps a Hold rating on the shares.
Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer as its new chief financial officer.
Resmed (RMD) announced that Brett Sandercock, CFO, plans to retire effective May 4. After conducting a search, Aaron Bloomer has been appointed as his successor. Bloomer joinsResmedfrom Exact Sciences...
Reports Q3 revenue $1.43B, consensus $1.42B. “Our third quarter results reflect the continued strength of our global business, driven by ongoing demand for our market-leading products and disciplined ...
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett...
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%...
KeyBanc lowered the firm’s price target on ResMed (RMD) to $290 from $302 to reflect lower peer multiples, while keeping an Overweight rating on the shares. The firm believes underlying…
JPMorgan initiated coverage of ResMed (RMD) with an Overweight rating and A$37.60 price target The firm says ResMed is the global leader in the obstructive sleep apnea market. While therapeutics,…
Evercore ISI analyst Anthony Petrone lowered the firm’s price target on ResMed (RMD) to $255 from $300 and keeps an Outperform rating on the shares. The firm adjusted estimates and…
Citi lowered the firm’s price target on ResMed (RMD) to $340 from $345 and keeps a Buy rating on the shares.
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2026 on Thursday, ...
Insights from 30,000 people across 13 countries show global sleep health awareness is growing, yet an action gap remains 53% of people surveyed rank sleep as the most important behavior for a long, h...
ResMed (RMD) stock is currently at a fascinating juncture. It is trading at a low price, and if you decide to invest in it, you are wagering on a company that is demonstrating reasonable growth, maint...
Resmed (RMD) is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed’s U.S. presence and strengthen the company’s distribution ...
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distributi...
Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling the GLP‑1 bo...
Citi analyst Laura Sutcliffe raised the firm’s price target on ResMed (RMD) to $345 from $330 and keeps a Buy rating on the shares.
RBC Capital analyst Craig Wong-Pan raised the firm’s price target on ResMed (RMD) to $314 from $311 and keeps an Outperform rating on the shares. The company delivered a strong…
KeyBanc analyst Brett Fishbin raised the firm’s price target on ResMed (RMD) to $302 from $299 and keeps an Overweight rating on the shares post Q2 on higher estimates. The…
Stifel raised the firm’s price target on ResMed (RMD) to $265 from $260 and keeps a Hold rating on the shares following fiscal Q2 results. While the firm calls it…
Baird raised the firm’s price target on ResMed (RMD) to $281 from $275 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results which…
Piper Sandler raised the firm’s price target on ResMed (RMD) to $275 from $270 and keeps a Neutral rating on the shares. The firm notes the company reported Q2 results…
Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep apnea.
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 1.60B | Analyst x7 | |
| 2027 | 1.70B | 5.84% | Analyst x7 |
| 2028 | 1.77B | 4.43% | Analyst x5 |
| 2029 | 1.83B | 3.43% | Analyst x1 |
| 2030 | 1.98B | 8.15% | Analyst x1 |
| 2031 | 2.05B | 3.44% | Est @3.4% |
| 2032 | 2.11B | 3.20% | Est @3.2% |
| 2033 | 2.18B | 3.04% | Est @3.0% |
| 2034 | 2.24B | 2.73% | Est @2.7% |
| 2035 | 2.30B | 2.65% | Est @2.7% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 1.30B | 1.00 | 1.30B |
| 2025A | 1.66B | 1.00 | 1.66B |
| 2026E | 1.60B | 1.09 | 1.48B |
| 2027E | 1.70B | 1.18 | 1.44B |
| 2028E | 1.77B | 1.28 | 1.38B |
| 2029E | 1.83B | 1.39 | 1.32B |
| 2030E | 1.98B | 1.51 | 1.31B |
| 2031E | 2.05B | 1.64 | 1.25B |
| 2032E | 2.11B | 1.78 | 1.19B |
| 2033E | 2.18B | 1.93 | 1.13B |
| 2034E | 2.24B | 2.10 | 1.07B |
| 2035E | 2.30B | 2.28 | 1.01B |
| Terminal | 38.69B | 2.28 | 16.98B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.